ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Scientists at the Quantitative Biosciences Institute at the University of California, San Francisco (UCSF) have launched Rezo Therapeutics with $78 million in series A funding. Drawing on close connections to its academic founders, the start-up wants to pioneer a computational approach that applies multiple technologies—proteomics, genetics, structural biology, chemistry, and bioinformatics—in parallel to probe disease mechanisms and identify drug targets. Rezo is advancing several therapeutic programs with an initial focus on solid tumor oncology.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X